Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2

被引:33
作者
Zhang, HF
Li, YW
Li, HL
Bassi, R
Jimenez, X
Witte, L
Bohlen, P
Hicklin, DJ
Zhu, ZP
机构
[1] ImClone Syst Inc, Dept Antibody Technol, New York, NY 10014 USA
[2] ImClone Syst Inc, Dept Immunol, New York, NY 10014 USA
[3] ImClone Syst Inc, Dept Mol & Cell Biol, New York, NY 10014 USA
[4] ImClone Syst Inc, Dept Res, New York, NY 10014 USA
关键词
angiogenesis; leukemia; autocrine and paracrine growth; VEGF/KDR; human antibody; leukemia therapy;
D O I
10.1080/10428190410001712225
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) have been implicated in promoting solid tumor growth and metastasis via stimulating tumor-associated angiogenesis. Here we show that certain "liquid'' tumors such as acute myeloid leukemia not only produce VEGF but also express functional VEGFR, resulting in an autocrine loop for tumor growth and propagation. In addition, the leukemia-derived VEGF can also stimulate the production of growth factors, including interleukin 6 (IL6) and granulocyte-macrophage colony stimulating factor (GM-CSF), by human endothelial cells, which in turn further promotes the growth of leukemia cells (the paracrine loop). A fully human anti-VEGFR2 (or kinase insert domain-containing receptor, KDR) antibody, IMC-2C6, strongly blocks KDR/VEGF interaction and neutralizes VEGF-stimulated activation of KDR in endothelial cells. In a system where leukemia cells are co-cultured with endothelial cells, IMC-2C6 inhibits both the production of IL6 and GM-CSF by endothelial cells and the growth of leukemia cells. Finally, IMC-2C6 effectively blocks VEGF-induced migration of KDR+ human leukemia cells, and when administered in vivo, significantly prolonged survival of mice inoculated with KDR+ human leukemia cells. Taken together, our data suggest that anti-KDR antibodies may have broad applications in the treatment of both solid tumors and certain types of leukemia.
引用
收藏
页码:1887 / 1897
页数:11
相关论文
共 57 条
[51]  
WU Y, 2003, P AM ASS CANC RES, V44
[52]   Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity [J].
Zhu, Z ;
Hattori, K ;
Zhang, H ;
Jimenez, X ;
Ludwig, DL ;
Dias, S ;
Kussie, P ;
Koo, H ;
Kim, HJ ;
Lu, D ;
Liu, M ;
Tejada, R ;
Friedrich, M ;
Bohlen, P ;
Witte, L ;
Rafii, S .
LEUKEMIA, 2003, 17 (03) :604-611
[53]   Clinical Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor and Its Receptors as Cancer Therapeutics [J].
Zhu, Zhenping ;
Bohlen, Peter ;
Witte, Larry .
CURRENT CANCER DRUG TARGETS, 2002, 2 (02) :135-156
[54]   Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody [J].
Zhu, ZP ;
Lu, D ;
Kotanides, H ;
Santiago, A ;
Jimenez, X ;
Simcox, T ;
Hicklin, DJ ;
Bohlen, P ;
Witte, L .
CANCER LETTERS, 1999, 136 (02) :203-213
[55]  
Zhu ZP, 1998, CANCER RES, V58, P3209
[56]   KDR receptor:: A key marker defining hematopoietic stem cells [J].
Ziegler, BL ;
Valtieri, M ;
Porada, GA ;
De Maria, R ;
Müller, R ;
Masella, B ;
Gabbianelli, M ;
Casella, I ;
Pelosi, E ;
Bock, T ;
Zanjani, ED ;
Peschle, C .
SCIENCE, 1999, 285 (5433) :1553-1558
[57]   General aspects of anti-angiogenesis and cancer therapy [J].
Zogakis, TG ;
Libutti, SK .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (02) :253-275